Menu Search
Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Learn moreSubscribe now
Equities

CanSino Biologics Inc

CJH:MUN

CanSino Biologics Inc

Actions
  • Price (EUR)3.26
  • Today's Change-0.12 / -3.55%
  • Shares traded--
  • 1 Year change+7.98%
  • Beta--
Data delayed at least 15 minutes, as of Nov 01 2024 07:03 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

CanSino Biologics Inc is a clinical-stage vaccine company in China. The Company's products include Ad5-EBOV vaccine used for Ebola virus, MCV2 and MCV4 vaccines for meningococcus, PBPV vaccine used for pneumococcal and the recombinant novel coronavirus vaccine. Its products are mainly used in meningitis, diphtheria pertussis tetanus (DPT) and pneumonia.

  • Revenue in HKD (TTM)665.61m
  • Net income in HKD-946.44m
  • Incorporated2009
  • Employees1.49k
  • Location
    CanSino Biologics IncWest District Biomedical Park, No. 185South Avenue, West District, EconomicTIANJIN 300457ChinaCHN
  • Phone+86 2 258213766
  • Fax+86 2 258213626
  • Websitehttp://www.cansinotech.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.